More than half of U.S. adults now qualify for a statin — and nearly every elderly inpatient you admit does
What happened — A new analysis out of Pitt and Michigan, covered this week, put hard numbers on the 2026 AHA/ACC multisociety dyslipidemia guideline. By widening risk assessment from ages 40–75 to 30–79, stretching the risk horizon from 10 years to 30, swapping the pooled cohort equations for the PREVENT equations, and adding stage 3+ CKD and HIV as standalone indications, the guideline made an additional 21.5 million adults statin-eligible — 87.5 million total, or 56.6% of adults 30–79. Eligibility climbs steeply with age: 93.5% of adults aged 70–79.
Why it matters to you — Effectively every geriatric admission on your service is now guideline-eligible for a statin, which means the interesting clinical question flips from "should we start one?" to "should we continue one?" The guideline's 30-year risk framing is built for a 45-year-old, not an 87-year-old with a two-year prognosis, advanced dementia, and eleven other pills. Expect more reflexive statin restarts at admission, more pushback when you deprescribe, and more family conversations that begin with "but the guidelines say."
Talking point: Worth raising at your next group meeting — a one-page internal note on statin continuation vs. deprescribing in patients >75 with limited life expectancy or goals-of-care limitations would land well right now, before the guideline filters into order sets and quality metrics.
Medscape ·
UPMC/Pitt ·
U-M IHPI
First oral PCSK9 inhibitor (enlicitide) lands — a pill, not an injection
What happened — Enlicitide, the first orally administered PCSK9 inhibitor, was approved and is being welcomed by primary care as a practical option for patients who can't tolerate statins or don't reach targets on them. Reported July 23.
Why it matters to you — Two reasons. First, it pairs directly with the statin story above: the pool of "eligible but statin-intolerant" patients just got much bigger, and a pill is a very different discharge conversation than teaching an elderly patient or a caregiver to self-inject every two weeks. Second, it's a formulary and cost question that will hit your discharge med recs before it hits your admissions — worth knowing whether it's on your hospital's formulary and what the outpatient prior-auth pathway looks like, so you're not promising something at discharge that stalls at the pharmacy counter.
Suggested action: Ask pharmacy this week where enlicitide sits on formulary and whether there's a PA pathway, so your discharge summaries can point patients somewhere real.
Medscape Internal Medicine
Update: First night without U.S. strikes on Iran in two weeks — talks confirmed, but Hormuz still unresolved
What happened — Iran reported no new U.S. strikes overnight into Saturday, the first such break in nearly two straight weeks of nightly attacks. Both sides confirmed talks are ongoing via mediators, though Tehran is still reviewing proposals and there's "not much progress yet," with fundamental differences over who controls passage through the Strait of Hormuz. Meanwhile the conflict is still spilling sideways: Saudi Arabia and the Houthis traded attacks, and Houthi strikes on two Saudi tankers in the Red Sea have made Bab el-Mandeb a second choke point alongside Hormuz.
Why it matters to you — This is the single biggest input into your pump price and your household energy bill right now. Brent slipped back below $98 on Friday but was still up more than 12% on the week; WTI eased toward $89. Hormuz transits were running at 15 a day against an 88-a-day pre-crisis baseline. A durable pause would take real pressure off fuel, freight, and the medical-supply costs that eventually show up in your hospital's budget conversations — but one quiet night isn't a trend.